Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,747 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Apple-shaped obesity: A risky soil for cytokine-accelerated severity in COVID-19.
Hosoya T, Oba S, Komiya Y, Kawata D, Kamiya M, Iwai H, Miyamoto S, Kataoka M, Tobiume M, Kanno T, Ainai A, Sato H, Hirakawa A, Mitsui Y, Satoh T, Wakabayashi K, Yamada T, Otomo Y, Miyazaki Y, Hasegawa H, Suzuki T, Yasuda S. Hosoya T, et al. Among authors: kanno t. Proc Natl Acad Sci U S A. 2023 May 30;120(22):e2300155120. doi: 10.1073/pnas.2300155120. Epub 2023 May 22. Proc Natl Acad Sci U S A. 2023. PMID: 37216518 Free PMC article.
Pathology of Kaposi's Sarcoma-Associated Herpesvirus Infection.
Fukumoto H, Kanno T, Hasegawa H, Katano H. Fukumoto H, et al. Among authors: kanno t. Front Microbiol. 2011 Aug 25;2:175. doi: 10.3389/fmicb.2011.00175. eCollection 2011. Front Microbiol. 2011. PMID: 21904536 Free PMC article.
Establishing and characterizing a new primary effusion lymphoma cell line harboring Kaposi's sarcoma-associated herpesvirus.
Osawa M, Mine S, Ota S, Kato K, Sekizuka T, Kuroda M, Kataoka M, Fukumoto H, Sato Y, Kanno T, Hasegawa H, Ueda K, Fukayama M, Maeda T, Kanoh S, Kawana A, Fujikura Y, Katano H. Osawa M, et al. Among authors: kanno t. Infect Agent Cancer. 2016 Aug 17;11:37. doi: 10.1186/s13027-016-0086-5. eCollection 2016. Infect Agent Cancer. 2016. PMID: 27536332 Free PMC article.
Temporal maturation of neutralizing antibodies in COVID-19 convalescent individuals improves potency and breadth to circulating SARS-CoV-2 variants.
Moriyama S, Adachi Y, Sato T, Tonouchi K, Sun L, Fukushi S, Yamada S, Kinoshita H, Nojima K, Kanno T, Tobiume M, Ishijima K, Kuroda Y, Park ES, Onodera T, Matsumura T, Takano T, Terahara K, Isogawa M, Nishiyama A, Kawana-Tachikawa A, Shinkai M, Tachikawa N, Nakamura S, Okai T, Okuma K, Matano T, Fujimoto T, Maeda K, Ohnishi M, Wakita T, Suzuki T, Takahashi Y. Moriyama S, et al. Among authors: kanno t. Immunity. 2021 Aug 10;54(8):1841-1852.e4. doi: 10.1016/j.immuni.2021.06.015. Epub 2021 Jul 2. Immunity. 2021. PMID: 34246326 Free PMC article.
Prolonged SARS-CoV-2 infection associated with long-term corticosteroid use in a patient with impaired B-cell immunity.
Morishita M, Suzuki M, Matsunaga A, Ishizhima K, Yamamoto T, Kuroda Y, Kanno T, Tsujimoto Y, Ishida A, Hashimoto M, Ishii S, Takasaki J, Naka G, Iikura M, Izumi S, Suzuki T, Maeda K, Ishizaka Y, Hojo M, Sugiyama H. Morishita M, et al. Among authors: kanno t. J Infect Chemother. 2022 Jul;28(7):971-974. doi: 10.1016/j.jiac.2022.02.006. Epub 2022 Feb 10. J Infect Chemother. 2022. PMID: 35184976 Free PMC article.
Vaccination-infection interval determines cross-neutralization potency to SARS-CoV-2 Omicron after breakthrough infection by other variants.
Miyamoto S, Arashiro T, Adachi Y, Moriyama S, Kinoshita H, Kanno T, Saito S, Katano H, Iida S, Ainai A, Kotaki R, Yamada S, Kuroda Y, Yamamoto T, Ishijima K, Park ES, Inoue Y, Kaku Y, Tobiume M, Iwata-Yoshikawa N, Shiwa-Sudo N, Tokunaga K, Ozono S, Hemmi T, Ueno A, Kishida N, Watanabe S, Nojima K, Seki Y, Mizukami T, Hasegawa H, Ebihara H, Maeda K, Fukushi S, Takahashi Y, Suzuki T. Miyamoto S, et al. Among authors: kanno t. Med. 2022 Apr 8;3(4):249-261.e4. doi: 10.1016/j.medj.2022.02.006. Epub 2022 Mar 4. Med. 2022. PMID: 35261995 Free PMC article.
Duration of Infectious Virus Shedding by SARS-CoV-2 Omicron Variant-Infected Vaccinees.
Takahashi K, Ishikane M, Ujiie M, Iwamoto N, Okumura N, Sato T, Nagashima M, Moriya A, Suzuki M, Hojo M, Kanno T, Saito S, Miyamoto S, Ainai A, Tobiume M, Arashiro T, Fujimoto T, Saito T, Yamato M, Suzuki T, Ohmagari N. Takahashi K, et al. Among authors: kanno t. Emerg Infect Dis. 2022 May;28(5):998-1001. doi: 10.3201/eid2805.220197. Epub 2022 Mar 15. Emerg Infect Dis. 2022. PMID: 35290176 Free PMC article.
A case report of breakthrough infection with the SARS-CoV-2 delta variant and household transmission: Role of vaccination, anti-spike IgG and neutralizing activity.
Moriyama Y, Ishikane M, Ueno M, Matsunaga A, Ishizaka Y, Arashiro T, Kanno T, Suzuki T, Kimura K. Moriyama Y, et al. Among authors: kanno t. J Infect Chemother. 2022 Jul;28(7):962-964. doi: 10.1016/j.jiac.2022.02.003. Epub 2022 Feb 11. J Infect Chemother. 2022. PMID: 35461768 Free PMC article.
Activation of SARS-CoV-2 neutralizing antibody is slower than elevation of spike-specific IgG, IgM, and nucleocapsid-specific IgG antibodies.
Takahashi M, Ai T, Sinozuka K, Baba Y, Igawa G, Nojiri S, Yamamoto T, Yuri M, Takei S, Saito K, Horiuchi Y, Kanno T, Tobiume M, Khasawneh A, Paran FJ, Hiki M, Wakita M, Miida T, Suzuki T, Okuzawa A, Takahashi K, Naito T, Tabe Y. Takahashi M, et al. Among authors: kanno t. Sci Rep. 2022 Sep 1;12(1):14909. doi: 10.1038/s41598-022-19073-z. Sci Rep. 2022. PMID: 36050347 Free PMC article.
Intranasal vaccination induced cross-protective secretory IgA antibodies against SARS-CoV-2 variants with reducing the potential risk of lung eosinophilic immunopathology.
Hemmi T, Ainai A, Hashiguchi T, Tobiume M, Kanno T, Iwata-Yoshikawa N, Iida S, Sato Y, Miyamoto S, Ueno A, Sano K, Saito S, Shiwa-Sudo N, Nagata N, Tamura K, Suzuki R, Hasegawa H, Suzuki T. Hemmi T, et al. Among authors: kanno t. Vaccine. 2022 Sep 29;40(41):5892-5903. doi: 10.1016/j.vaccine.2022.08.049. Epub 2022 Aug 26. Vaccine. 2022. PMID: 36064667 Free PMC article.
1,747 results